These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28852974)

  • 21. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
    Han CS; Patel R; Kim IY
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.
    Wang Y; Dason S; Shayegan B
    Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abiraterone acetate as a possible cause of sudden cardiac death.
    Sahin S; Karatas F; Eren T; Altinbas M; Altundag K
    J BUON; 2016; 21(3):751-2. PubMed ID: 27569102
    [No Abstract]   [Full Text] [Related]  

  • 25. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
    Svensson J; Andersson E; Persson U; Edekling T; Ovanfors A; Ahlgren G
    Scand J Urol; 2016 Aug; 50(4):286-91. PubMed ID: 27109827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
    Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
    J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
    Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
    Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
    Beardo-Villar P; Ledo-Cepero MJ; Gavira-Moreno R; Soto-Delgado M; Soto-Villalba J; Alvarez-Ossorio JL; Juárez-Soto A
    Actas Urol Esp; 2014 Jun; 38(5):339-45. PubMed ID: 24480574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
    Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
    Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; De Cobelli O; Nolè F
    Eur J Cancer; 2015 Sep; 51(14):1970-7. PubMed ID: 26169016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
    Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
    BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
    Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
    J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Corticotherapy in castration-resistant prostate cancer].
    Lebdai S; Branchereau J; Robert G; De La Taille A; Bouchaert P
    Prog Urol; 2013 Oct; 23 Suppl 1():S23-33. PubMed ID: 24314736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis.
    Roviello G; Generali D
    Med Oncol; 2018 Jan; 35(3):29. PubMed ID: 29387974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials.
    Ferro M; Di Lorenzo G; de Cobelli O; Bruzzese D; Pignataro P; Borghesi M; Musi G; Vartolomei MD; Cosimato V; Serino A; Ieluzzi V; Terracciano D; Damiano R; Cantiello F; Mistretta FA; Muto M; Lucarelli G; De Placido P; Buonerba C
    World J Urol; 2019 Jun; 37(6):1049-1059. PubMed ID: 30519742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.